| 1. |
- Jankowski, V, et al.
(författare)
-
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by MALDI-TOF-TOF-mass spectrometric analysis
- 2005
-
Ingår i: Hypertension. - 1524-4563. ; 46:3, s. 591-597
-
Tidskriftsartikel (refereegranskat)abstract
- Angiotensin II ( Ang II) is the major vasoactive component of the renin- angiotensin system. Several components of the renin- angiotensin system have been demonstrated in different tissues. Whereas the roles of tissue and renal renin- angiotensin system have been studied in detail, much less is known on whether the corpuscular elements of circulating blood contribute to Ang II production. Here we examined whether, in addition to vasculature, blood cells also contribute to the circulating Ang II levels. Mononuclear leukocytes were obtained from healthy subjects and were incubated. The resulting supernatant was chromatographed using different chromatographic methods. The vasoconstrictive effects of aliquots of the resulting fractions were tested. Each fraction with a vasoconstrictive effect was analyzed by mass spectrometry. In one fraction with a strong vasoconstrictive effect, Ang II was identified. Mononuclear lymphocytes produced Ang II in amounts sufficient to stimulate Ang II type 1 receptors. Moreover, in mononuclear leukocytes, renin as well as angiotensin- converting enzyme mRNA expression was detectable by RT- PCR. These findings demonstrate that mononuclear leukocytes are a source of Ang II. Ang II secretion by these cells may play a significant role in humoral vascular regulation. In conclusion, the isolation of Ang II in supernatants of mononuclear leukocytes adds a further physiological source of Ang II to the current view of angiotensin metabolism. The quantitative role of lymphocyte- derived Ang II secretion compared with the other sources of Ang II should be defined further, but the release found under the present conditions is at least sufficient to elicit vasoconstrictive effects
|
|
| 2. |
- Hinz, Michael, et al.
(författare)
-
Variability of paths and differential equations with BV-coefficients
- 2023
-
Ingår i: Annales de l'I.H.P. Probabilites et statistiques. - : Institute of Mathematical Statistics. - 0246-0203 .- 1778-7017. ; 59:4, s. 2036-2082
-
Tidskriftsartikel (refereegranskat)abstract
- We define compositions phi(X) of Holder paths X in Rn and functions of bounded variation phi under a relative condition involving the path and the gradient measure of phi. We show the existence and properties of generalized Lebesgue-Stieltjes integrals of compositions phi (X) with respect to a given Holder path Y. These results are then used, together with Doss' transform, to obtain existence and, in a certain sense, uniqueness results for differential equations in Rn driven by Holder paths and involving coefficients of bounded variation. Examples include equations with discontinuous coefficients driven by paths of two-dimensional fractional Brownian motions.
|
|
| 3. |
- Marchettini, P, et al.
(författare)
-
Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
- 2016
-
Ingår i: European Journal of Pain. - : Wiley. - 1090-3801 .- 1532-2149. ; 20:3, s. 472-82
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: To investigate baseline demographics and disease characteristics as predictors of the analgesic effect of duloxetine and pregabalin on diabetic peripheral neuropathic pain (DPNP).METHODS: Based on data from the COMBO-DN study, a multinational clinical trial in DPNP, the potential impact of baseline characteristics on pain relief after 8-week monotherapy with 60 mg/day duloxetine or 300 mg/day pregabalin was assessed using analyses of covariance. Subgroups of interest were characterized regarding their baseline characteristics and efficacy outcomes.RESULTS: A total of 804 patients were evaluated at baseline. A significant interaction with treatment was observed in the mood symptom subgroups with a larger pain reduction in duloxetine-treated patients having no mood symptoms [Hospital Anxiety and Depression Scale (HADS) depression or anxiety subscale score <11; -2.33 (duloxetine); -1.52 (pregabalin); p = 0.024]. There were no significant interactions between treatment for subgroups by age (<65 or ≥65 years), gender, baseline pain severity [Brief Pain Inventory Modified Short Form (BPI-MSF) average pain <6 or ≥6], diabetic neuropathy duration (≤2 or >2 years), baseline haemoglobin A1c (HbA1c) (<8% or ≥8%), presence of comorbidities and concomitant medication use.CONCLUSIONS: Our analyses suggest that the efficacy of duloxetine and pregabalin for initial 8-week treatment in DPNP was consistent across examined subgroups based on demographics and disease characteristics at baseline except for the presence of mood symptoms. Duloxetine treatment appeared to be particularly beneficial in DPNP patients having no mood symptoms.
|
|
